Key result
Heart failure hospitalization after PCI was associated with a higher risk of subsequent mortality than ACS or major bleeding.
Why the study?
Current guidelines and quality metrics after PCI often assign equal weight to nonfatal adverse events in composite endpoints, prompting the need to quantify and compare their associations with subsequent mortality.
Do nonfatal adverse events (HFH, ACS, major bleeding) have different associations with subsequent mortality in patients undergoing PCI?
Cohort (n=10,482)
Yes
Do nonfatal adverse events (HFH, ACS, major bleeding) have different associations with subsequent mortality in patients undergoing PCI?
Heart failure hospitalization following PCI is associated with a significantly higher subsequent mortality risk and population burden than ACS or major bleeding, challenging the equal weighting of these events in composite endpoints.
Answers are grounded in this paper and cite their sources.
HFH after PCI signals highest subsequent mortality risk; hypothesis-generating for reweighting events in composite endpoints.
BACKGROUND Current guidelines and quality metrics after percutaneous coronary intervention (PCI) often assign equal weight to nonfatal adverse events, including heart failure hospitalization (HFH), acute coronary syndrome (ACS), and major bleeding, within composite endpoints. OBJECTIVES The aim of this study was to quantify and compare the associations of HFH, ACS, and major bleeding with subsequent mortality following PCI. METHODS A Japanese multicenter prospective PCI registry (2008-2021) with 2-year postprocedural outcomes was analyzed. The primary outcome was all-cause mortality, with HFH, ACS, and major bleeding as time-varying exposures. Cumulative incidence was estimated with death as a competing risk. Cox proportional hazards models and population attributable fractions were used to assess associations between time-varying events and mortality, adjusting for conventional risk factors. RESULTS Among 10,482 patients (mean age 69 years, 77.5% men) followed for a median of 730 days (Q1-Q3: 730-730 days), 1,021 (9.7%; 95% CI: 9.2%-10.3%) experienced adverse events. Two-year cumulative incidence rates were 4.7% (95% CI: 4.2%-5.1%) for HFH, 3.4% (95% CI: 3.0%-3.7%) for ACS, and 2.5% (95% CI: 2.2%-2.8%) for major bleeding. Cox analysis showed that HFH was associated with mortality (adjusted HR [aHR]: 6.11; 95% CI: 4.76-7.85), followed by ACS (aHR: 3.22; 95% CI: 2.14-4.84) and major bleeding (aHR: 2.62; 95% CI: 1.71-4.02). Population attributable fraction analysis demonstrated that HFH accounted for 20.1% (95% CI: 19.0%-21.0%) of mortality burden, higher than ACS (4.3%; 95% CI: 3.3%-4.9%) and major bleeding (2.9%; 95% CI: 1.9%-3.5%). CONCLUSIONS HFH shows stronger associations with mortality than ACS or major bleeding following PCI, suggesting that adverse events should not be weighted equally and underscoring the need to reconsider prioritization in clinical decision-making and endpoint definitions.
No takes yet. Share an insight, caveat, or question.
Shiraishi et al. (2026) conducted a cohort in Patients undergoing percutaneous coronary intervention (n=10,482). Heart failure hospitalization, acute coronary syndrome, and major bleeding was evaluated on All-cause mortality (aHR 6.11 (HFH), aHR 3.22 (ACS), aHR 2.62 (major bleeding), 95% CI 4.76-7.85 (HFH), 2.14-4.84 (ACS), 1.71-4.02 (major bleeding)). Heart failure hospitalization after PCI was associated with a higher risk of subsequent mortality than ACS or major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: